UNSPSC 51272600: Anaesthetic isonipecotic acids

Anaesthetics based on compounds derived from 4-piperidinecarboxylic acid, a piperidine ring with a carboxylic acid moiety, as its name suggests.

UNSPSC 51272600 Anaesthetic isonipecotic acids is a Class code, but the recent state and local opportunities posted under it do not align with the code's nominal pharmaceutical chemistry scope. The three most recent solicitations—Seminole County's IFB for Naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescriptions, and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products—target supply, distribution, and program-design work for finished pharmaceutical products, not the chemical compound class the code nominally describes. The mismatch suggests either mistagging in the source data or a state procurement system that applies this Class code to broader pharmaceutical procurement activity. State and local buying under this code appears to span health department and multistate cooperative purchasing organizations seeking to procure pharmaceuticals and related health products through competitive processes, with emphasis on compliance, wholesaler relationships, pricing transparency, and quarterly or periodic delivery.

Activity concentrates in Florida and Texas, with Minnesota administering a multistate cooperative that includes Oregon participation. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023, though posted June 30, 2026—a date discrepancy in the source) requesting 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP. The Minnesota Department of Administration, through MMCAP, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on administrative compliance and EDI capability. All three solicitations require E-Verify compliance, insurance coverage, and adherence to FDA or federal regulatory standards.